STM Journals Peer-reviewed research from Consortium e-Learning Network

Recent Trends in Cosmetics Review Article

Effect of Skin Barrier Damage on Absorption and Action of Cosmeceuticals

  1. Suraj Sen Dept. of Pharmacy, Harishchandra Pharmacy College
  2. Anit Jha Dept. of Pharmacy, Harishchandra Pharmacy College
  3. Praveen Yadav Dept. of Pharmacy, Harishchandra Pharmacy College
  4. Ujala Dept. of Pharmacy, Harishchandra Pharmacy College
  5. Anushka Maurya Dept. of Pharmacy, Harishchandra Pharmacy College

Abstract

The skin acts as a primary defensive barrier protecting the human body against environmental aggressors, microbial invasion, and chemical exposure. The integrity of the skin barrier, particularly the stratum corneum, plays a crucial role in regulating the permeation of substances applied topically. Cosmeceuticals, a hybrid category between cosmetics and pharmaceuticals, are designed to deliver biologically active ingredients into the skin to exert therapeutic or beneficial effects. However, the condition of the skin barrier significantly influences their absorption, efficacy, and safety. Skin barrier damage may arise due to intrinsic factors such as aging and genetic predisposition, as well as extrinsic factors including UV radiation, pollution, harsh chemicals, and excessive use of skincare products. Disruption of the barrier leads to increased transepidermal water loss (TEWL), altered lipid composition, and compromised structural organization, which in turn affects percutaneous absorption pathways. While mild barrier impairment may enhance penetration of active ingredients, severe damage can lead to uncontrolled absorption, irritation, inflammation, and systemic exposure risks. This review comprehensively explores the relationship between skin barrier damage and the absorption dynamics of cosmeceuticals. It discusses the structural and functional aspects of the skin barrier, mechanisms of its disruption, and fundamental principles of transdermal drug delivery. Additionally, the article highlights how formulation strategies can be optimized for compromised skin conditions, ensuring both efficacy and safety. Current research trends, clinical implications, and regulatory considerations are also addressed to provide a holistic understanding of this critical area.

Keywords

References (52)

  1. Elias PM. The skin barrier as an innate immune element. InSeminars in immunopathology
  2. 2007 Apr (Vol. 29, No. 1, pp. 3-14). Berlin/Heidelberg: Springer-Verlag.
  3. Bouwstra JA, Ponec M. The skin barrier in healthy and diseased state. Biochimica et
  4. Biophysica Acta (BBA)-Biomembranes. 2006 Dec 1;1758(12):2080-95.
  5. Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Experimental
  6. dermatology. 2008 Dec;17(12):1063-72.
  7. KC M. Barrier function of the skin:" la raison d'etre" of the epidermis. J Invest Dermatol.
  8. 2003;121:231-41.
  9. Hadgraft J. Skin, the final frontier. Int J Pharm. 2001;224:1–18.
  10. Barry BW. Dermatological formulations: percutaneous absorption. CRC Press; 2002.
  11. Kilgman AM. Cosmeceuticals: A broad-spectrum category between cosmetics and drugs.
  12. Cosmeceuticals and Active Cosmetics. Drug Versus Cosmetics. Boca Rotan, FL: Taylor and
  13. Francis. 2005 Mar 1.
  14. Williams AC, Barry BW. Penetration enhancers. Advanced drug delivery reviews. 2012 Dec
  15. 1;64:128-37.
  16. Rawlings AV, Harding CR. Moisturization and skin barrier function. Dermatologic therapy.
  17. 2004 Feb;17:43-8.
  18. Lodén M. Role of topical emollients and moisturizers. Am J Clin Dermatol.
  19. 2003;4:771–788.
  20. Flynn GL, Stewart B. Percutaneous drug penetration: choosing candidates for transdermal
  21. development. Drug Development Research. 1988;13(2‐3):169-85.
  22. Benson HA. Transdermal drug delivery: penetration enhancement techniques. Current drug
  23. delivery. 2005 Jan 1;2(1):23-33.
  24. Biju S, Talegaonkar S, Mishra P, Khar R. Vesicular systems: An overview. Indian journal of
  25. pharmaceutical sciences. 2006 Mar 1;68(2):NA-.
  26. Prausnitz MR, Langer R. Transdermal drug delivery. Nature biotechnology. 2008
  27. Nov;26(11):1261-8.
  28. Menon GK. New insights into skin structure: scratching the surface. Advanced drug delivery
  29. reviews. 2002 Nov 1;54:S3-17.
  30. Draelos ZD. Cosmeceuticals: undefined, unclassified, and unregulated. Clinics in
  31. dermatology. 2009 Sep 1;27(5):431-4.
  32. Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the
  33. treatment of skin aging: an overview of clinical efficacy and safety. Clinical interventions in
  34. aging. 2006 Jan 1;1(4):327-48.
  35. Tanghetti EA. The role of inflammation in the pathology of acne. The Journal of clinical and
  36. aesthetic dermatology. 2013 Sep;6(9):27.
  37. Thiele JJ, Dreher F, Packer L. Antioxidant defense systems in skin. Journal of Toxicology:
  38. Cutaneous and Ocular Toxicology. 2002 Jan 1;21(1-2):119-60.
  39. Korting HC, Schäfer-Korting M. Carriers in the topical treatment of skin disease. Drug
  40. delivery. 2009 Nov 19:435-68.
  41. Puglia C, Bonina F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal
  42. pharmaceuticals. Expert Opinion on Drug Delivery. 2012 Apr 1;9(4):429-41.
  43. Bissett DL. Common cosmeceuticals. Clinics in dermatology. 2009 Sep 1;27(5):435-45.
  44. Rawlings AV. The stratum corneum and aging. Textbook of aging skin. 2010:55-75.
  45. Grice EA, Segre JA. The skin microbiome. Nature reviews microbiology. 2011 Apr;9(4):244-
  46. Elias PM, Wakefield JS, Man MQ. Moisturizers versus current and next-generation barrier
  47. repair therapy for the management of atopic dermatitis. Skin pharmacology and physiology.
  48. 2018 Dec 14;32(1):1-7.
  49. Benson HA, Watkinson AC. Topical and transdermal drug delivery. 2011.
  50. Walters KA, editor. Dermatological and transdermal formulations. CRC press; 2002 Feb 20.
  51. Gupta D. Colloidal carriers in ophthalmic drug delivery. InNano-Biomaterials For Ophthalmic
  52. Drug Delivery 2016 Nov 13 (pp. 321-349). Cham: Springer International Publishing.